Two failed transfers. Both times, good embryos. Both times, the lining looked fine. Both times, nothing.
That sequence is one of the most disorienting experiences in fertility treatment. No obvious explanation. No clear next step. And often, nobody asking the question that should have come up earlier: are we transferring at the right time?
The ERA test exists because “the right time” is not the same for every woman, and the assumption that it is has been quietly behind a significant proportion of unexplained implantation failures. Not a small number. Not an edge case. A meaningful, documentable subset of patients whose cycles failed not because of embryo quality or uterine anatomy, but because the transfer happened outside their actual receptive window.
The Assumption Baked Into Standard Protocol
Standard frozen embryo transfer (FET) protocols are built on population averages. The endometrium is prepared with oestrogen, then progesterone. After a fixed number of progesterone days, typically five for a blastocyst transfer, the embryo goes in. The assumption embedded in this is that five days of progesterone produces endometrial receptivity in essentially every patient.
That assumption is wrong for roughly 20-30% of women.
The window of implantation, the specific period during which the endometrium expresses the molecular signals needed to receive an embryo, shifts earlier or later than average in a substantial minority of patients. For some women, optimal receptivity occurs after four days of progesterone. For others, six. The window itself may last only 12-24 hours. Transfer outside it, even by a single day, and the embryo encounters a lining that is either not yet ready or already past its receptive phase.
Ultrasound cannot see this. A trilaminar pattern at 8mm tells you the endometrium has responded to hormonal preparation. It tells you nothing about the gene expression profile underneath. That’s the gap ERA addresses.
What the Test Involves
ERA stands for Endometrial Receptivity Analysis. A small endometrial biopsy is taken during a mock transfer cycle that mirrors the patient’s actual FET protocol, at the exact point when transfer would normally occur. If the standard protocol uses five days of progesterone, the biopsy is taken on day five, at the same time of day transfer would happen.
The sample goes to a laboratory where the expression of 248 genes associated with endometrial receptivity is analysed and compared against a validated reference database. The result classifies the endometrium as pre-receptive, receptive, or post-receptive. If it falls outside the receptive window, a specific progesterone timing adjustment is provided.
The adjusted transfer that follows is called a personalised embryo transfer (pET). Instead of the population-average protocol, the cycle uses timing corrected to the patient’s actual biology.
The biopsy itself takes a few minutes and is comparable in discomfort to a standard transfer. The mock cycle requires the same endometrial preparation as a real FET, which adds a cycle to the timeline. That’s worth knowing upfront, because the delay frustrates people, understandably, and it’s better to understand why it’s necessary before you’re in the middle of it.
Who It’s Actually For
ERA is not warranted for every IVF patient, and the clinics recommending it universally are not following the evidence. They’re following the margin.
The clearest indication is recurrent implantation failure: two or more failed transfers with good-quality embryos and no identified structural cause. ERA test for recurrent implantation failure is where the evidence is strongest. A hysteroscopy has assessed the uterine cavity. PGT-A has confirmed embryo chromosomal status. What hasn’t been directly tested is whether the transfer is happening at the right moment in that specific patient’s biology.
ERA is also worth considering for patients with irregular progesterone responses, patients on non-standard protocols, and patients with thin endometrium where receptivity may be further compromised.
Where ERA has weak justification: first or second transfers in patients with no prior implantation failure. The prevalence of displaced implantation windows in an unselected population is lower, and the probability that timing is the primary issue when nothing has yet failed is considerably less. Adding a test and a cycle delay before there is clinical reason to suspect timing is the variable doesn’t help the patient. It helps the invoice.
Six Scenarios That Show When ERA Changes the Outcome and When It Doesn’t
Consider six hypothetical profiles that show when ERA is clinically warranted, when it isn’t, and what the results can mean in practice.
The first: a 35-year-old with two failed FETs, both using PGT-A confirmed euploid blastocysts, both with good endometrial lining on transfer day. Hysteroscopy normal. Thrombophilia screen negative. Immunology panel unremarkable. ERA is recommended before using the final euploid embryo. The biopsy, taken at the standard five-day progesterone point, comes back post-receptive. The window is earlier than the protocol assumed. Transfer is moved to four days plus eighteen hours of progesterone. In a profile like this, the prior failures were not unexplained bad luck. They were a timing problem that standard monitoring could not detect.
The second: a 40-year-old with one failed fresh transfer and one failed FET, both with unscreened embryos. A third cycle banks blastocysts for PGT-A. Three euploid embryos in storage. Before any are transferred, ERA is run. Result: pre-receptive at five days. Personalised window requires six days of progesterone. First euploid transfer at corrected timing results in pregnancy. In this hypothetical, the patient had attributed earlier failures to embryo quality. The embryo quality problem was real and was solved by PGT-A. But a separate timing problem existed simultaneously, only identified through ERA. Two distinct problems requiring two distinct investigations.
The third: a 33-year-old with one failed euploid transfer and documented progesterone variability across prior cycles, with serum levels on transfer day consistently running lower than expected despite standard dosing. ERA is recommended not purely on the basis of one failure, but because the progesterone data already flags atypical endometrial progression. ERA confirms pre-receptive status at five days. Adjusted transfer at six days results in pregnancy. ERA here confirmed what the existing clinical data was already suggesting.
The fourth: a hypothetical 29-year-old on her first FET after a freeze-all cycle, no prior failures, good reserve, high-quality blastocysts in storage. ERA is offered as an optional add-on. The clinical recommendation is against it. No implantation history suggests timing is an issue. The test adds cost and a cycle with no evidence-based rationale in this profile. She transfers on standard timing. Successful pregnancy. ERA was not needed. This scenario matters as much as the cases where it works. A diagnostic tool used before there is a clinical problem to diagnose is not thoroughness. It is unnecessary expenditure.
The fifth: a 38-year-old with three failed transfers, the third using a confirmed euploid embryo. ERA after the second failure had returned receptive at five days, confirming her timing was correct. The third failure, with a chromosomally normal embryo and correct timing, prompts a different investigation. ALICE testing reveals chronic endometritis, asymptomatic but impairing implantation. Antibiotic treatment follows. The next euploid transfer, with correct timing and a treated endometrium, results in pregnancy. ERA answered the timing question correctly. The endometritis was a separate problem ERA was not designed to detect.
The sixth: a hypothetical first-time IVF patient, no failed transfers, no prior fertility treatment, who specifically requests ERA after researching it independently. The clinical recommendation is to proceed with a standard first transfer and reserve ERA for investigation if implantation fails. For a patient with no implantation history, the prior probability of a displaced window is lower than in recurrent failure cases. The cost and cycle delay are not justified by the evidence in this profile. She transfers on standard timing. Successful pregnancy. ERA was never indicated for her, which is the point.
What the Evidence Shows and Where Clinics Misrepresent It
ERA has good evidence in its intended population: patients with recurrent implantation failure. The original validation studies and subsequent clinical data from pET protocols show improved implantation rates in patients with prior failed transfers when personalised timing is applied.
What is more contested: ERA in unselected patients. A randomised controlled trial in the New England Journal of Medicine found ERA-guided transfers did not improve live birth rates compared to standard timing in an unselected FET population. This is the finding that responsible clinics acknowledge and the ones chasing revenue quietly ignore.
The clinical consensus is sensible: ERA is a diagnostic tool for a defined problem, not a universal optimisation step. Used for the right patients, the evidence supports it. Applied to everyone, it adds cost without improving outcomes. Any clinic unable to draw that distinction clearly in a consultation is telling you something important about how they make clinical decisions.
What ERA Costs in India
Endometrial receptivity analysis cost in India is considerably lower than equivalent testing in Western markets, where the analysis alone runs £500-800 in the UK and $800-1,200 in the US.
A realistic breakdown:
- ERA biopsy and laboratory analysis: ₹35,000-60,000 at accredited centres, depending on whether EMMA and ALICE are run simultaneously from the same sample
- Mock transfer cycle preparation (medications and monitoring): ₹15,000-25,000
- Total ERA workup before the actual transfer cycle: ₹50,000-85,000 approximately
The ERA analysis itself is conducted by Igenomix, the laboratory that developed and validated the test. Most centres send biopsy samples there regardless of location, so cost variation between clinics reflects primarily the biopsy fee and cycle preparation rather than differences in the underlying analysis.
At 9M Fertility, ERA test for IVF in Hyderabad is recommended based on your specific transfer history, embryo quality data, and clinical profile. The indication is reviewed before the recommendation is made. It is not a default add-on.
Tests That Come Alongside ERA
ERA is frequently offered with EMMA (Endometrial Microbiome Metagenomic Analysis) and ALICE (Analysis of Infectious Chronic Endometritis). All three use the same biopsy sample, which is clinically efficient when all three are indicated.
EMMA assesses the bacterial composition of the uterine microbiome. Reduced Lactobacillus dominance has been associated in some studies with lower implantation rates. ALICE tests specifically for pathogens associated with chronic endometritis, a low-grade infection that can be asymptomatic but is increasingly recognised as a factor in recurrent implantation failure.
Bundling all three from a single biopsy is defensible when the clinical history supports investigating all three. Automatic bundling without specific rationale for each is not. Patients are entitled to ask which tests are being recommended, why each is indicated for their specific situation, and what the plan is if any of them comes back positive.
Timing Is Not Everything. But Sometimes It’s the One Thing Nobody Checked.
ERA doesn’t fix embryo quality. It doesn’t address uterine anatomy. It doesn’t change ovarian reserve. It answers one specific question that standard monitoring cannot: is the endometrium molecularly receptive at the moment of transfer?
For most patients, the answer is yes, and standard protocol timing is correct. For a meaningful minority, it isn’t, and that discrepancy has been behind failed transfers that had no other explanation.
The patients who benefit from ERA are not those optimising their first transfer. They’re the ones who’ve been told their embryos were good and their lining looked fine, and who still ended up with nothing. If that’s where you are, personalised embryo transfer timing is not a speculative extra. It’s the question that should have been asked a cycle earlier.
ERA test for IVF in Hyderabad at 9M Fertility is recommended when your clinical picture makes timing a logical variable to investigate. If you’ve had failed transfers with good embryos and no structural explanation, that conversation is worth having before your next cycle begins.
Book a consultation at 9M Fertility.
→ Also read: PGT-A Testing: How Genetic Screening Can Improve Your IVF Success Rate
→ Also read: Egg and Embryo Freezing: Everything You Need to Know About Vitrification
